The use of genetically modified mouse models and in vitro cell culture models
October 2, 2020
Here we introduce a new screening strategy for antibody drugs, by which not only can people minimize the risk of potential “red flags”, but also reduce the time and cost.
Events
- Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA | July 07, 2021
- Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars | June 22, 2021
- Celebrating World CRISPR Day | October 29, 2020
- Webinar: Antibody Discovery Platforms and RenMab Mouse | June 29, 2020
- Webinar: Humanized Animal Models for Immunotherapy | June 29, 2020
- Experts in Genetically Engineered Animal Development and Maintenance | September 19, 2019
- Symposium: Future of Biologic Drug Discovery and Development | June 13, 2019
News
- Team Building in the White Mountains | July 27, 2021
- Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA | July 07, 2021
- Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars | June 22, 2021
- Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1 | March 23, 2021
- Biocytogen announces acquisition of a third Beacon Optofluidic system | March 05, 2021
- Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab | February 10, 2021
- Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement | February 01, 2021
- Biocytogen Enters into RenMab™/RenLite™ Licensing Agreement with Xencor | December 07, 2020
- Biocytogen Teams With Ina Research To Boost Presence In Japan | December 04, 2020
- Festival of Biologics Basel 2020 | November 02, 2020
- Immuno-Oncology Summit Virtual Summit 2020 | October 01, 2020
- Emerging biotechnology company Biocytogen raised 142 million dollars (USD) in support of Project Integrum | September 24, 2020
- Strategic collaboration agreement reached between Biocytogen and Berkeley Lights for second Beacon Optofluidic system | September 18, 2020
- PEGS Boston Virtual Summit | August 20, 2020
- RenMab™ and RenLite™ Models Featured in GEN Magazine | August 19, 2020
- RenMab™ Mouse Platform Drives SARS CoV-2 Neutralizing Antibody Cocktail Therapy Towards Clinical Trials in Biocytogen and Eucure Biopharma Partnership | August 13, 2020
- Biocytogen is Featured in GEN’s Immunotherapy and Cancer Supplement Issue | April 10, 2020
- Biocytogen CEO’s Response During COVID-19 Pandemic | April 08, 2020
- Gene Targeting Service Verified with Industry-leading Quality Control Measures | March 12, 2020
- GEN Magazine Mentions Biocytogen and Its Humanized Mice Model | March 06, 2020
- Nature Research Webcast: Accelerating therapeutic antibody discovery with fully human antibody mice | November 26, 2019
- The Utility of the Rosa26 Knock-in Mouse | November 19, 2019
- RenMab™ Mouse Featured in GEN Magazine | November 08, 2019
- Biocytogen’s RenMab™ Mouse is Featured on Fiercebiotech | October 28, 2019
- Biocytogen Closes $79M Series D Funding | August 09, 2019
- Biocytogen’s President & CEO, Dr. Yuelei Shen, Speaks at Harvard China Forum at Harvard University | April 15, 2019
- Biocytogen’s Integrated One-stop Preclinical Services and the RenMab Mouse Shine at AACR 2019 | April 07, 2019
